Background: The effects of statin administration on kidney disease outcomes remain controversial. We undertook a systematic review and meta-analysis to assess the efficacy of statins on kidney outcomes.
INDEX WORDS: Chronic kidney disease (CKD); kidney disease outcomes; kidney failure; statins; hydroxymethylglutaryl-CoA reductase inhibitor; lipid lowering; dyslipidemia; atorvastatin; rosuvastatin; simvastatin; pravastatin; estimated glomerular filtration rate (eGFR); proteinuria; albuminuria; cardiovascular events; systematic review. C hronic kidney disease (CKD) is a major health problem and is associated with increased risk for all-cause mortality, cardiovascular disease, and endstage renal disease (ESRD). [1] [2] [3] [4] [5] Abnormal lipid metabolism is common in patients with kidney disease. 6 Experimental studies have shown that dyslipidemia is causally associated with glomerular injury, resulting in glomerulosclerosis. 7, 8 Post hoc analyses of several large trials have demonstrated that dyslipidemia is significantly associated with increased risk for developing reduced kidney function or faster estimated glomerular filtration rate (eGFR) decline in a general population without kidney disease. 9, 10 The effects of statins on kidney disease progression remain controversial. Several trials have evaluated the effects of statins on kidney disease outcomes. Although some trials have shown benefits of statins, [11] [12] [13] others have shown no effect. [14] [15] [16] Thus, there is uncertainty about the presence and magnitude of their renal protective effects. Furthermore, most published articles were based on post hoc analyses of cardiovascular benefits of statin treatment. A previous overview of trials using patients with or without kidney disease found that statin therapy decreased proteinuria and led to a slight decrease in the rate of kidney function loss, mainly in a population of patients with early kidney disease. 17 However, the large Study of Heart and Renal Protection (SHARP) included 6,245 participants with advanced CKD and found that statin administration did not reduce the risk for kidney failure or rate of change in eGFR. 14 Prior systematic reviews have provided strong evidence to suggest that statin therapy reduced the risk for major vascular events, as well as death, in patients with kidney disease across a wide range of kidney function. [18] [19] [20] With this systematic review, our aim was to synthesize all available clinical trial information for statin administration in people with or without kidney disease and evaluate the efficacy of statins on kidney outcomes.
METHODS

Data Sources and Search Strategy
We performed this systematic review according to a prespecified protocol (Item S1, available as online supplementary material) and reporting was done in line with PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analyses) guidelines. 21 Relevant studies were identified by searching the following data sources: MEDLINE by Ovid (from 1946 to August 31, 2015), EMBASE (from 1966 to August 31, 2015), and the Cochrane Library database (Cochrane Central Register of Controlled Trials; no date restriction), with relevant text words and medical subject headings that included all spellings of "kidney," "kidney function tests," "glomerular filtration rate," "proteinuria," "hydroxymethylglutaryl-CoA reductase inhibitor," "simvastatin," "atorvastatin," "rosuvastatin," and "pravastatin" (Item S1). Trials were considered without language restriction. To ensure a comprehensive literature search, we examined reference lists from included articles. The ClinicalTrials.gov website was also searched for randomized trials that were registered as completed but not yet published.
Study Selection and Outcome Estimation
We included data from randomized controlled trials (RCTs) in which a statin was given for at least 6 months to adults who were not receiving dialysis, irrespective of whether participants had CKD at baseline, and for which kidney outcomes, including kidney failure events, eGFR, or proteinuria data, were reported.
The primary outcome was kidney failure events, including .25% or 50% decrease in eGFR, doubling of serum creatinine level, or ESRD as defined by the authors of each study during the follow-up period. If more than one of the methods for defining kidney failure event was provided by a study, we used that reporting more events for increased study power. Secondary outcomes included the following. ). Positive differences in the rate of change in eGFR represent a slower decline in the statin group than in the control group. 2. Change in proteinuria or albuminuria from baseline to end of follow-up. Results from urinary protein excretion or urinary albumin excretion were converted to grams per 24 hours. Results from protein-creatinine ratio (PCR) or albumin-creatinine ratio (ACR) were converted to milligrams per gram of creatinine. Negative differences in change in proteinuria represent a greater decrease in the statin group than in the control group. 3. Effect of statin administration on major cardiovascular events in a subgroup of patients with CKD (defined as a composite including fatal or nonfatal myocardial infarction, fatal or nonfatal stroke, revascularization procedures, cardiovascular death, and heart failure or comparable definitions used by individual authors).
Data Extraction and Quality Assessment
Published reports were obtained for each eligible trial, and relevant information was extracted into a spreadsheet. The data sought included study characteristics (design, method of randomization, and withdrawals/dropouts); baseline patient characteristics (age, sex, cause of kidney disease, mean proteinuria or albuminuria, eGFR, fasting serum low-density lipoprotein cholesterol [LDL-C] concentration); type of statin used; dose of drug; follow-up duration; change in eGFR, proteinuria or albuminuria, and LDL-C concentrations; and outcome events. When the required quantitative data were not provided in relevant articles, we used g3 data software (www.frantz.fi/software/g3data.php) to extract exact numbers from published figures. 18 We evaluated all potentially relevant sources of bias using the Cochrane Collaboration risk of bias tool, 22, 23 including assessment of financial conflicts of interest as has been recommended. 24 We developed operational definitions for high, low, and unclear risk of bias for each of the 7 domains (Item S2). We summarized both individual ( Fig S1) and aggregate ( Fig S2) risk of bias data for the included studies. The literature search, study selection, data extraction, and quality assessment were undertaken independently by 2 authors (X.S. and L.Z.) using a standardized approach according to the predefined protocol (Item S1). Disagreement was resolved by consensus or by discussion with a third author (J.L.).
Data Synthesis and Analysis
Individual patient data were not available from the studies in this analysis, so tabular data were used. If odds ratios (ORs) were unavailable in the original article, individual study ORs and 95% confidence intervals (CIs) were calculated from event numbers and the total population at risk extracted from each trial before data pooling. In consideration of potential heterogeneity among the included studies, which cannot be avoided, the random-effects model was applied using the empirical Bayes procedure 25 with Knapp-Hartung modification based on t distribution 26 to analyze all outcomes. Simultaneously, DerSimonian-Laird 27 and restricted maximum likelihood 28 estimators with CIs contructed by normal distribution 23, 27 or Knapp-Hartung approach 26 were also performed as sensitivity analysis. For a binary outcome, a fully Bayesian method assuming a binomial likelihood on the log-odds scale rather than normal approximation was implemented by WinBUGS (Medical Research Council Biostatistics Unit).
29, 30 We used noninformative priors with vague normal (mean, 0; variance, 100,000) and uniform (0-1) prior distributions for parameters. Three Markov chain Monte Carlo chains of 55,000 iterations each were used to compute the posterior distributions, after 5,000 burn-in iterations (see codes in Item S3). We used the Brooks-Gelman-Rubin statistic and inspection of trace plots to check for convergence of Markov chain Monte Carlo chains. 31 Mean differences were used to pool rates of change in eGFRs, which were defined as difference from baseline in eGFR divided by number of years between creatinine measurements. Standardized mean differences were used to pool results from all studies that reported changes in proteinuria or albuminuria (including urinary albumin excretion, urinary protein excretion, ACR, or PCR). When data for change from baseline were available in the included trials, we directly extracted them from the literature. When the change-from-baseline standard deviation was missing, we calculated it using correlations that were estimated from other included studies that had a similar follow-up period and reported in considerable detail according to the imputed formulation and its related interpretations in Cochrane Handbook. 23 We replaced missing mean data with median data. 32 Missing standard deviation data were imputed using interquartile range (dividing by 1.35 only when large sample size), 23 full range (dividing the range by values  from the table of critical values for Pearson table) , 33, 34 or reported P value. 23 Summary estimates of mean differences and standardized mean differences were also obtained using a random-effects model.
The percentage of variability across studies attributable to heterogeneity beyond chance was estimated using the I 2 statistic. We explored potential heterogeneity by comparing summary results obtained from subsets of studies grouped by number of patients, mean age, type and doses of statin, follow-up duration, baseline mean LDL-C concentrations and their differences in changes, baseline mean eGFR, baseline mean proteinuria or albuminuria, and different participants by classifying them in CKD (either proteinuria or GFR # 60 mL/min/1.73 m 2 ) and non-CKD groups, as well as cardiovascular disease and non-cardiovascular disease groups.
Between-subgroup heterogeneity was assessed by c 2 test and metaregression.
35 A 2-sided P , 0.05 was considered statistically significant, and statistical analyses were performed using Metafor packages from R software, version 3. 
RESULTS
Search Results and Characteristics of Included Studies
The literature search yielded 4,192 articles, of which 176 were reviewed in full text (Fig 1) . As shown in Table 1 and Table S1 , a total of 57 eligible trials reported in 67 publications 11-18,36- The reported trial quality varied substantially ( Figs  S1 and S2 ). In the meta-analysis for primary outcome, data were obtained from studies that generally had lower risk of bias than other included studies: random sequence generation was assessed as low risk in 57%, allocation concealment was low risk in 50%, participants and personnel were blinded in 93%, outcome assessors were blinded in 79%, and attrition and reporting bias were low risk in 86%. However, in meta-analyses for secondary outcome, data were obtained from studies with higher risk of bias (Fig S1) . In all included studies, biases of conflicts of interest from pharmaceutical industry study funding and author-industry financial relationships were high risk in 40% and 42%, respectively (Figs S1 and S2). In order to investigate reporting/published bias, we searched and found that 27 studies reported their protocols in 176 full-text peer-reviewed articles. In studies in which no outcomes of interest for this systematic review were reported, we did not find any preplanned kidney outcome. Fig S3) . This effect was mainly dominated by the TNT (Treating to New Targets) Study. 36 There was no statistical heterogeneity in all subgroup analyses apart from the borderline significance for effects of different types of statins (P 5 0.07; Table S2 ).
Effect of Statins on Designated Outcomes
The effect of statin administration on rate of change in eGFR was available in 47 trials of 128,601 participants. [11] [12] [13] [14] [15] [16] [36] [37] [38] [39] When considering studies that were placebo or usual-care controlled, statin therapy slowed the rate of eGFR decline by 0.41 mL/min/ 1.73 m 2 per year (95% CI, 0.11-0.70; Fig 3) . There was evidence of significant heterogeneity for effects across included studies (I 2 5 90%; 95% CI, 87%-92%). Intensive lipid lowering reduced the rate of eGFR decline by 0.35 (95% CI, 0.27-0.42) mL/min/1.73 m 2 per year (Fig S4) . Compared to rosuvastatin or simvastatin, atorvastatin significantly slowed the rate of eGFR decline in direct comparison trials (mean differences of 2.45 and 0.33, respectively; Fig S5) . Subgroup analysis showed that there was heterogeneity for the effects of different types of statins (P , 0.001; Table 2 ).
Effect on Proteinuria and Albuminuria
Twenty-nine trials with 4,968 participants reported data regarding the effects of statins on changes in proteinuria or albuminuria. Of these, 11 studies with a total of 2,833 participants provided data for urinary protein excretion 12 ; 5 studies with 788 participants, ACR 60, 71, 76, 82 ; and 1 study with 120 participants, PCR. 69 The standardized mean difference in change in proteinuria or albuminuria was statistically significant at 20.65 (95% CI, 20.94 to 20.37) compared with the placebo or usual-care control groups, with substantial Fig S6) . Similar to results seen with rate of change in eGFR, subgroup analysis showed that there was heterogeneity for the effects of different types of statins (P , 0.001; Table 2 ).
Effect on Major Cardiovascular Events in CKD Patients
Data regarding effects of statin administration on major cardiovascular events in patients with CKD were available from 13 publications 13, 15, 12, 57, 37, 39, 38, 56, 11, 52, 14, 55, 50 comprising 15 trials, including 34,853 participants and 5,491 events. Overall, statin therapy significantly reduced the risk for cardiovascular events (OR, 0.69; 95% CI, 0.61-0.79; P , 0.001) without evidence of heterogeneity in results of individual trials (I 2 5 33%; 95% CI, 0%-66%; Fig S7) .
Sensitivity Analysis
Results did not vary using different random-effects estimation methods (Fig S8; Table S3 ).
DISCUSSION
There is epidemiologic and clinical evidence supporting the idea that dyslipidemia is a risk factor for CKD initiation or progression. 9, 10, 95 Effects of statin administration on kidney disease outcomes remain controversial. This large quantitative review, including 57 trials, more than 140,000 participants, and 8,498 kidney failure events, suggests that statin therapy produces a mild reduction in proteinuria and rate of decline in eGFR of 0.41 mL/min/1/73 m 2 per year. However, these effects did not translate into a risk reduction of kidney failure events. Similar to our prior study, 18 this study showed that statin therapy induced a 30% risk reduction in major cardiovascular events in patients with CKD. Although this study did not show clear renal benefits, the lack of evidence for an adverse effect of statin on kidney outcomes is important, particularly in light of the clear cardiovascular benefits of statins.
The large volume of data available was beneficial for this meta-analysis. To our knowledge, the current study represents the largest systematic review of statin administration on kidney disease progression and the first meta-analysis that evaluates the effect of statin treatment on kidney failure events. Several prior overviews have evaluated effects of statins on kidney disease outcomes in patients with cardiovascular risk or CKD. Meta-analyses that included 26 trials with 39,704 participants reported significant benefits of statins, with differences in eGFR decline of 1.22 (95% CI, 0.44-2.00) mL/min per year. 17 A recent review that included 41 studies with a total of 88,523 patients found that statin therapy reduced the slope of eGFR decline. 96 However, both studies focused on effects of proteinuria reduction or eGFR decline and not on clinically relevant renal benefits, such as kidney failure events. Additionally, these studies cannot exclude the possibility that statin administration increases creatinine excretion and influences serum creatinine level. The findings of these studies therefore have limited application in clinical practice. Our study, which examined nearly double the number of participants in prior reviews, found a nonsignificant beneficial effect in composite kidney failure events and ESRD. This finding aligns with SHARP, a large trial. 14 However, this study might not be the final answer for the question of lowering LDL-C levels and progression of kidney disease. First, the study cannot exclude that intensive LDL-C lowering would have an effect on reducing the risk for kidney disease progression. We observed that an intensive strategy reduced the risk for kidney failure by 31% compared to the usual dose ). Second, there is heterogeneity in terms of the effects of kidney protection among different types of statins. In direct comparison trials, atorvastatin was reported to confer the greatest renal benefit. Furthermore, atorvastatin, pravastatin, and simvastatin showed a trend in reducing the risk for kidney failure, with the pooled risk reduction for kidney failure of 6% (95% CI, 1%-12%), whereas other statins did not show the same effect. The current study cannot exclude the possibility of a more moderate kidney protective effect of some statins. Despite its large size, even SHARP did not reach sufficient statistical power to detect such a modest proportional risk reduction, in which the relative risk reduction for kidney failure or doubling of serum creatinine level was 7% (95% CI, 21% to 14%; P 5 0.09).
14 A population of nearly 20,000 patients will be required for a future study to have sufficient power to demonstrate an absolute risk reduction in patients with high risk for kidney disease progression and whether such a risk reduction is clinically relevant. IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial), which had 18,144 participants, has provided an example of a 6% Figure 4 . Forest plot for change in proteinuria or albuminuria. Negative values in difference of change represent greater decreases for proteinuria or albuminuria in statin group than in control group. Abbreviations: ACR, albumin-creatinine ratio; CI, confidence interval; PCR, protein-creatinine ratio; SD, standard deviation; SMD, standard mean difference; UAE, urinary albumin excretion; UPE, urinary protein excretion.
relative cardiovascular risk reduction with ezetimibe therapy, which translates into a worthwhile absolute risk reduction in patients with coronary disease. 97, 98 Statin administration for kidney protection remains to be debated. Regardless, statins also should be used for patients with kidney disease and high-risk cardiovascular disease when considering atherosclerotic disease according to the KDIGO (Kidney Disease: Improving Global Outcomes) lipid guidelines and European lipid guidelines.
The study has some potential limitations. First, post hoc analyses from large RCTs accounted for a considerable proportion of the study's included trials (21 of 57 trials). Most large RCTs of statins were principally designed to evaluate cardiovascular outcomes in persons presenting with cardiac disease. They were not specifically designed to test kidney function. In secondary outcome analyses, the relative paucity of high-quality RCTs limited the conclusions able to be drawn about eGFR and proteinuria, although the quality of the studies included in the primary outcome was considered good. Second, we found evidence of substantial heterogeneity in secondary outcome analyses, although we tried to address this by using random-effects models. We acknowledge the possibility that this heterogeneity had an impact on our results. Third, findings related to changes in proteinuria are based on a much smaller number of patients (n 5 4,977) compared with the other analyses. Fourth, as discussed, a potential effect on creatinine generation and/or tubular secretion from statin treatment has not been removed. 99 Large prospective randomized trials including measured (not estimated) GFR are needed to definitively prove a positive effect of statins on kidney function progression. Fifth, we included only published studies in this analysis, and reporting bias could not be excluded because not all studies reported each outcome. In particular, kidney outcomes were not primary end points in most included trials and thus it is likely that some were not reported because they were not significant. Because we did not find an overall benefit of statins on kidney failure, this effect may be limited. However, this may produce much bias in comparison of a high versus low dose of statin for which a renal benefit was shown in 3 high-dose statin therapy trials. Finally, there were 21 missing standard deviations of change in eGFR and proteinuria, and we used the imputation of correlation referred to in the Cochrane Handbook. 23 We concede that doing so may produce uncertainty and underestimate the width of CIs, although most of these missing standard deviations were from trials with relatively small sample sizes.
In conclusion, this review suggests that statin therapy does not reduce the risk for kidney disease progression in adults not receiving dialysis in whom kidney disease outcomes were reported. However, statin therapy seems to modestly reduce proteinuria and rate of eGFR decline. The effects of kidney protection may differ according to the type of statin. The clinical significance of the results requires confirmation with further studies. tion, analysis, and interpretation of data; writing the report; and the decision to submit the report for publication.
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